Last reviewed · How we verify
Duobrii 0.01 % / 0.045 % Topical Lotion
Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis.
At a glance
| Generic name | Duobrii 0.01 % / 0.045 % Topical Lotion |
|---|---|
| Sponsor | Austin Institute for Clinical Research |
| Drug class | Topical corticosteroid + retinoid combination |
| Target | Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Halobetasol propionate is a Class I (super-potent) topical corticosteroid that suppresses inflammatory cytokines and immune cell infiltration in the skin. Tazarotene is a third-generation retinoid that binds retinoic acid receptors to promote keratinocyte differentiation and reduce hyperproliferation. The combination provides complementary anti-inflammatory and anti-proliferative effects for enhanced efficacy in plaque psoriasis.
Approved indications
- Plaque psoriasis
Common side effects
- Application site irritation
- Application site burning
- Application site pruritus
- Skin atrophy
Key clinical trials
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: